Analyst Ratings for Ligand Pharma (LGND)
LGND Rating Summary
LGND Price Target Summary
- Highest: $388.00 (BofA Securities)
- Lowest: $285.00 (Oppenheimer)
- Average: $335.75
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$335.75 (+9.9%)
* Over Last 12-Mos
Rating Score: 7 / 10
Percentile Rank: 74%
Avg. $ Target:
$335.75 (+9.9%)
* Over Last 12-Mos
Rating Score: 7 / 10
Percentile Rank: 74%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/21/2026 | Citi | Yigal Nochomovitz | New Coverage | Buy (N/A) |
387.00 (N/A) |
293.99 (305.47) |
3.9% | Details |
| 5/4/2026 | Oppenheimer | Leland Gershell | New Coverage | Outperform (N/A) |
285.00 (N/A) |
227.44 (305.47) |
34.31% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
